Baxter BioPharma Solutions

Sterile Injectables Contract Manufacturing

Support services for parenteral products

Baxter's contract manufacturing organisation (CMO) BioPharma Solutions offers form / fill / finish services for injectables.

With a successful combination of strong collaborations and 85 years of injectable drug experience, the company provides manufacturing services for a wide range of pharmaceutical drugs, including for the areas of oncology, biologics, antibody-drug conjugates (ADC), and vaccines. These are applicable for a variety of sterile dosage forms, including pre-filled syringes, cartridges, diluents for reconstitution, prefilled syringes, and lyophilised / liquid vials.

Baxter BioPharma Solutions helps clients with challenges in clinical supply, formulation, risk mitigation, patent expiry, scale-up of production, and addresses rises and falls in market demand.

Each solution is tailored specifically for each individual case, meeting clinical, commercial, traditional, and complex issues in sterile manufacturing.

Sterile current good manufacturing practice (cGMP) production facilities

With more than 50 manufacturing facilities worldwide, Baxter BioPharma's award-winning current good manufacturing practice (cGMP) production facilities provide unique, high-value collaboration opportunities. The company's extensive global network utilizes a key systemic approach to cGMP manufacturing to share efficiencies and expertise.

Baxter BioPharma Solutions' manufacturing units have recently won 2016 Facility of the Year (FOYA) award for Operational Excellence; 2012, 2013, 2015, 2016, and 2017 CMO Leadership Awards from Life Science Leader magazine; and the 2010, 2011, 2012, and 2015 Best Contract Manufacturing Organization at the Vaccine Industry Excellence Awards.

Syringe, cartridge, and vial filling for sterile products

Based in Bloomington in Indiana, Baxter BioPharma Solutions' state-of-the-art 600,000ft² campus is one of the largest contract manufacturers of sterile products in North America. This facility helps clients develop and manufacture quality products and packaging, with particular expertise in regulation and lyophilisation.

Contract manufacturing of oncology products

Baxter BioPharma Solutions' facility in Halle in Germany focuses on the manufacturing of cytotoxic and highly potent drugs. With more than 60 years of experience, the facility is certified by Safebridge and provides clinical and commercial production, with integrated technologies and services.

The recently expanded facility is dedicated to contract manufacturing of oncology products, such as cytotoxic, highly potent compounds, and ADCs. It received the FOYA in 2016 for Operational Excellence. Capabilities include liquid and dry powder filling, sterile crystallisation, disperse systems, clinical and commercial-scale lyophilisers, and flexible compounding areas.

Formulation and process development expertise with a wide variety of drug categories

Helping tackle technical challenges such as technology transfer and formulation, process, and analytical development, Baxter BioPharma Solutions' teams help clients develop freeze-fried dosage forms, solutions, and suspensions for full optimisation of drug products throughout manufacturing.

The company provides expertise in optimisation and development in lyophilisation, converting drugs from a lyophilised to a liquid state through reformulation, converting drugs from vial to prefilled syringe form, analysing extractables and leachables, and selecting components, including flexible containers, syringes, vials, and stoppers.

Baxter BioPharma Solutions' scientific team provides a large amount of industry experience across a wide variety of drug categories, including vaccines (adjuvant, conjugate), biologics (monoclonal antibodies, therapeutic proteins), cytotoxics, highly potent compounds, and antibody-drug conjugates (ADC).

Lyophilization Center of Excellence

Increasing stability for injectables and improving lyophilisation cycle times are vital parts of parenteral product development. With this optimisation, Baxter BioPharma Solutions formed the Lyophilization Center of Excellence to act as a resource centre for the production of high-quality freeze-drying.

Scientists and educators Dr Steven Nail and Wendy Saffel-Clemmer lead Baxter's development team to assist with the modification and reformulations that optimise lyophilised products. The company offers:

  • Cost-effective and targeted lab-to-product correlation for optimum product manufacturing
  • State-of-the-art equipment for the detection of aggregation and other stability problems
  • Automatic loading and unloading of lyophilisers to minimise microbial exposure and handling
  • Top analytical methods for protein biophysical characterisation and measurement of aggregates
  • Capillary electrophoresis expertise, including capillary isoelectric focusing (cIEF) and capillary gel electrophoresis (cGE)
  • Four research freeze-dryers for development of cycles for future clinical manufacture
  • Proven scientific approach to cycle development, verses traditional methods of trial-and-error

Contact Details

Baxter Healthcare Corporation
BioPharma Solutions
One Baxter Parkway
Deerfield, IL 60015
United States of America
Contact: Laura Salo
+1 800 4 Baxter
Cytotoxic Manufacturing and Highly Potent Compound Manufacturing
Cartridge Fill Finish
Liquid Vial Fill Finish
Lyophilized Vial Fill Finish
Prefilled Syringe Fill Finish

Available White Papers


A Clinical Perspective on IV Medication Delivery 29 August 2017 Management of medication delivery through intravenous (IV) administration is a complex and challenging task for pharmacists.


Best Practices in Formulation and Lyophilization Development: Proteins, monoclonal Antibodies (mAb), and Antibody Drug Conjugates (ADC) 07 February 2017 The ultimate goal of formulation development is a stable product. In the case of a protein product, that can be defined as delivering the correct dose, in the native secondary and tertiary structure, without unintended chemical modifications and free of extrinsic and intrinsic particles.


Pharmaceutical Development for ADCs 09 February 2015 Formulation, process and analytical development for antibody-drug conjugates (ADCs) can be complex.


The Scientific Path to Cycle Development: Optimizing the Lyophilization Process 26 March 2014 Management of medication delivery through lyophilization, freeze-drying, is a crucial enabling process technology for many important parenteral drugs.